Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Inclusion Criteria:

• Documented diagnosis of malignant solid tumor with measurable disease
• Life expectancy of at least 12 weeks
• ECOG performance status of 0, 1, or 2

Exclusion Criteria:

• Recent major surgery, radiation therapy or anti-cancer treatment
• History of any other prior malignancy within the last 5 years